Master of Science in Biotechnology Program, UW-Madison

Find Us On: M.S. in Biotechnology program on Facebook M.S. in Biotechnology program on Twitter M.S. in Biotechnology program on LinkedIn M.S. in Biotechnology program on YouTube

  • UW-Madison and BiotechnologyA Global Leader in a Growing Field
  • Alumni Perspectives VideosHear M.S. in Biotechnology alumni in their own words.
  • Alumni Case Study: Kim Hartz, Class of 2010"I wanted a program with meaning and value."
  • Alumni Case Study: Chuck Dokken, Class of 2009"I wanted this program to be a game changer for me—and it was."
  • Alumni Case Study: Sridevi Kameswaran, Class of 2011"Biotechnology is the future—and I'm prepared for it."
UW-Madison and Biotechnology1 Alumni Perspectives Videos2 Alumni Case Study: Kim Hartz, Class of 20103 Alumni Case Study: Chuck Dokken, Class of 20094 Alumni Case Study: Sridevi Kameswaran, Class of 20115

A program as unique as you are.

The Master of Science in Biotechnology offers:

  1. A curriculum like no other that integrates topics in science, business and law
  2. Powerful skills that bring the "big picture" of life science product development and commercialization into clear focus
  3. Exclusive evening/weekend courses allowing you to work full-time while enrolled, and
  4. A completed degree in less than two years

What's Being Taught This Week?

Year II: Early Drug Discovery
Introduction to Drug Discovery and Target Identification
Thursday, September 3, (6:00 PM - 8:00 PM)
and Friday morning (8:00 AM - 12:00 PM)
Location: Conf. Room 50, MG&E Building, University Research Park

Faculty Instructors: Gene McNally, Ph.D.; Dave Lewis, Ph.D. and Thomas Machleidt, Ph.D.

After this session, the student should be able to: 1. Outline the drug discovery process beginning with target identification up to pre-clinical trials and illustrate one iterative loop that commonly occurs in drug discovery. Describe at least two improvements in a potential therapeutic molecule that you would expect by going through this reiterative process. 2. Understand basic concepts for researching primary scientific literature and be prepared to implement the basic concepts provided that enable good presentation and paper writing skills. 3. Understand the general process of target identification via investigation of molecular mechanisms of diseases. Describe possible mechanisms of disease for the examples given and current and potential drug targets. 4. Understand new advances in single cell biology and some applications in drug discovery.

Year II: Business of Biotechnology: Commercialization Pathways
Course Introduction; Intro to Value Creation through Technology Commercialization and Guest Speaker on IP Strategies and Introduction to Business Law
Friday, September 4, (1:00 PM - 5:00 PM)
Location: Conf. Room 50, MG&E Building, University Research Park

Faculty Instructor: Cheryl Vickroy

After an introduction to the course, we will have an overview of technology commercialization as a key, value-producing activity. We will touch on how successful commercialization affects society and why it underpins many economic development efforts. We will begin to understand why a technology is not a business and how different technologies are brought to market in dis-similar ways. Using a business model canvas, you will sketch out your initial assumptions about your assigned technology within your project team. This session will also introduce common business law practices including entity formation, employment law and related concepts.

Featured Speaker

  • Daniel Cooper, J.D.
    Shareholder with Reinhart, Boerner, Van Dueren, SC, Madison and Milwaukee WI
Year II: Molecular Technologies III
Introduction to Molecular Technologies III and Data Analysis; Kinase Assay Laboratory
Saturday, September 5, (8:00 AM - 12:00 PM)
Location: BioPharmaceutical Technology Center Institute lab

Faculty Instructor: Natalie Betz, Ph.D.

Following a description of the course, the students will perform a fluorescent kinase technology (TR-FRET) for the verification of potency of the four test compounds identified in an initial compound screen against our target protein kinase Abl. In addition to determining the potency of our test compounds against our target kinase (Abl), a different kinase (Protein Kinase A  PKA) will also be tested for the ability of the test compounds to inhibit the activity of a kinase in a different family (i.e. off-target effects). Undesirable off-target effects can increase the toxicity of a potential drug and thus its clinical utility.

Question about the degree?
Contact Kurt

Kurt Zimmerman
Phone: (608) 262-0685
Contact Kurt Zimmerman, Director, M.S. in Biotechnology Program, UW-Madison

Question about admissions?
Contact Lynn

Lynn Schroeder
Program Manager
Phone: (608) 262-9753
Contact Lynn Schroeder, Program Manager, M.S. in Biotechnology Program, UW-Madison